ArticleFrontiers in oncology2022
Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Non-Invasive Assessment of Microvascular Invasion Risk in Hepatocellular Carcinoma Using Liquid Biopsy: Translational Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Identification of novel circulating protein biomarkers for hepatocellular carcinoma superior to alpha-fetoprotein through a stemness index and secretome analysis.World journal of surgical oncology · 2026Article
- Machine Learning-Based Models for the Prediction of Postoperative Recurrence Risk in MVI-Negative HCC.Biomedicines · 2025Article
- Current Advances in Classification, Prediction and Management of Microvascular Invasion in Hepatocellular Carcinoma.Journal of cellular and molecular medicine · 2025Review
- Evaluating the efficacy of using large language models in preoperative prediction of microvascular invasion in HCC: a multicenter study.Scientific reports · 2025Article
- Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.BMC cancer · 2025Observational
- Comparative Genomic Analysis of Key Oncogenic Pathways in Hepatocellular Carcinoma Among Diverse Populations.Cancers · 2025Article
- Advances in multi-omics studies of microvascular invasion in hepatocellular carcinoma.European journal of medical research · 2025Review
- Comparative genomic analysis of key oncogenic pathways in hepatocellular carcinoma among diverse populations.medRxiv : the preprint server for health sciences · 2025Article
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis.Scientific reports · 2025Article
- Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review.Cancers · 2024Review
- The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.Frontiers in immunology · 2024Article
- The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh recurrence incidence and poor survival after hepatectomy are enormous threats to hepatocellular carcinoma (HCC) patients, which can be caused by microvascular invasion (MVI). However, it is difficult to predict preoperative MVI status. In this study, we focus on cancer genomic alterations to comprehensively explore potential MVI and early recurrence biomarkers and provide clues to the mechanisms of HCC invasion and metastasis.
methodsForty-one patients with initially suspected HCC who were undergoing hepatectomy were finally enrolled. High-throughput targeted sequencing was performed on genomic alterations in their preoperative plasma and surgical fresh tumor tissues utilizing the 1,021-gene panel.
resultsHCC patients without MVI had longer RFS than MVI ones (
conclusionThe integration of a panel containing specific mutated genes and ctDNA maximal VAF for predicting MVI and early recurrence of HCC may achieve better performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.